Apollomics, Inc. (NASDAQ:APLM) Short Interest Update

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 2,900 shares, a decrease of 98.3% from the October 31st total of 168,500 shares. Based on an average daily volume of 283,800 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Apollomics stock. George Kaiser Family Foundation boosted its stake in shares of Apollomics, Inc. (NASDAQ:APLM) by 2,585.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 670,976 shares of the company’s stock after purchasing an additional 645,992 shares during the period. Apollomics makes up approximately 0.0% of George Kaiser Family Foundation’s portfolio, making the stock its 18th biggest holding. George Kaiser Family Foundation owned approximately 0.75% of Apollomics worth $141,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 19.13% of the company’s stock.

Apollomics Stock Performance

NASDAQ APLM opened at $8.16 on Thursday. The business’s 50-day moving average price is $13.03 and its 200 day moving average price is $17.48. Apollomics has a twelve month low of $7.55 and a twelve month high of $118.00.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.